Strong performance by Fagron, Arseus Medical & Corilus
Key points 2010:
-
Turnover growth of 8.4% to € 424.1 million
-
REBITDA increases 14.7% to € 60.4 million
-
EBIT increases 17.9% to € 36.0 million
-
Recurrent net profit per share increases 21.0% to € 0.98
-
Dividend proposal 2010: € 0.44 per share, 22% higher than in 2009
-
Outlook for 2011: Turnover growth of between 8% and 12%, organic turnover growth of between 3% and 6% and a REBITDA that is expected to grow faster than turnover
Ger van Jeveren, CEO of Arseus: ‘2010 was once again an excellent year for Arseus. As a result of the continuing professionalisation of the organisation and the widely communicated cost awareness, the recurrent EBITDA, the EBIT and net profit grew faster than turnover in 2010.
In the operational field, a firm foundation was laid in 2010 for the future growth of Arseus and its four divisions. With acquisitions in the US and Brazil, Fagron became the global market leader in pharmaceutical compounding. The operational and financial developments at Arseus Medical were impressive. Corilus introduced its software with success in new markets. This is a confirmation of the quality of the organisation as well as the software of Corilus. With the successful restructuring and the cost-saving programme, Arseus Dental has laid a foundation for growth in 2011.
In line with forecasts announced earlier, we expect turnover growth in 2011 of between 8% and 12%, organic growth of between 3% and 6% and a REBITDA that grows faster than turnover.’
Please open the link below for the full press release: